Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.
Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal
Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as HARMONi-2. Last June, Summit Therapeutics created a lot of buzz
September 5, 2024